AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30192907 — intervention group
Group type: EXPERIMENTAL
Intervention: Any type of suggestion (walking or antisedentary)
Number of subjects: 44
Study 30192907 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking suggestion
Number of subjects: 44
Study 30192907 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisedentary suggestion
Number of subjects: 44
Study 28747210 — intervention group
Group type: EXPERIMENTAL
Intervention: Souvenaid
Number of subjects: 34
Study 28747210 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 25887358 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 µg
Number of subjects: 142
Study 25887358 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 1.2 mg
Number of subjects: 142
Study 25887358 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 1.8 mg
Number of subjects: 142
Study 25887358 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 142
Study 25887358 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 1.2 mg and 1.8 mg
Number of subjects: 142
Study 25887358 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 142
Study 25887358 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 142
Study 23578669 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment (endovascular surgery, coiling, clipping) for UIAs larger than 5 mm
Number of subjects: 879
Study 23578669 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (observation) for UIAs
Number of subjects: 879
Study 21274557 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil p.o.
Number of subjects: 12
Study 21274557 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil p.o.
Number of subjects: 12
Study 21274557 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg iloprost inhalation
Number of subjects: 12
Study 21274557 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 19248129 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 50 mg
Number of subjects: 170
Study 19248129 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 150 mg
Number of subjects: 170
Study 19248129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 18246014 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium cages (TC)
Number of subjects: 83
Study 18246014 — intervention group
Group type: COMPARATOR
Intervention: Femoral ring allografts (FRA)
Number of subjects: 83
Study 15499697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab combined with methotrexate
Number of subjects: 0
Study 15499697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab alone
Number of subjects: 0
Study 15499697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 15499697 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study 11274518 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9041991 — intervention group
Group type: EXPERIMENTAL
Intervention: IV IgG (Polyglobin, n = 14, total dosage: 18 mL/kg)
Number of subjects: 29
Study 9041991 — intervention group
Group type: EXPERIMENTAL
Intervention: IV IgGMA (Pentaglobin, n = 13, total dosage: 15 mL/kg)
Number of subjects: 29
Study 9041991 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (IgG and IgGMA)
Number of subjects: 29
Study 7610025 — intervention group
Group type: EXPERIMENTAL
Intervention: Biplane rotational DSA
Number of subjects: 33
Study 7610025 — intervention group
Group type: COMPARATOR
Intervention: Conventional biplane DSA
Number of subjects: 33
Study 3307795 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 229
Study 3307795 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229
Study 29156941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia care management (DCM)
Number of subjects: 317
Study 29156941 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 317
Study 27401564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous or oral fluconazole at 6 mg/kg of body weight twice weekly
Number of subjects: 141
Study 25762749 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (VAR) tablets and placebo patches
Number of subjects: 108
Study 25762749 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets and nicotine patches
Number of subjects: 108
Study 21610201 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 (25-800 mg)
Number of subjects: 60
Study 21610201 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 with high-fat meal
Number of subjects: 60
Study 21610201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19880786 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintain testosterone and estradiol at eugonadal levels for young men (GnRH agonist + testosterone gel)
Number of subjects: 4
Study 19880786 — intervention group
Group type: EXPERIMENTAL
Intervention: Block testosterone's conversion to estradiol (GnRH agonist + testosterone gel + aromatase inhibitor)
Number of subjects: 4
Study 19880786 — intervention group
Group type: EXPERIMENTAL
Intervention: Induce hypogonadism (GnRH agonist alone)
Number of subjects: 4
Study 19880786 — intervention group
Group type: COMPARATOR
Intervention: All placebo
Number of subjects: 4
Study 17980667 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (up to 400 mg/day for 9 months)
Number of subjects: 412
Study 15966755 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR 2000 mg once daily
Number of subjects: 16
Study 15966755 — intervention group
Group type: COMPARATOR
Intervention: Metformin IR 1000 mg twice daily
Number of subjects: 16
Study 12483717 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of MRA
Number of subjects: 45
Study 12483717 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of MRA
Number of subjects: 45
Study 12483717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12483717 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg and 10 mg/kg of MRA
Number of subjects: 45
Study 12483717 — intervention group
Group type: EXPERIMENTAL
Intervention: All MRA cohorts
Number of subjects: 45
Study 10488265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal bacteriostatic 0.9% sodium chloride containing the preservative benzyl alcohol
Number of subjects: 40
Study 10488265 — intervention group
Group type: COMPARATOR
Intervention: Intradermal lidocaine hydrochloride 1%
Number of subjects: 40
Study 8133085 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 1726
Study 2777395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore-tex catheter
Number of subjects: 20
Study 2777395 — intervention group
Group type: COMPARATOR
Intervention: Oreopoulos catheter
Number of subjects: 20
Study 1089399 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 24
Study 1089399 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 24
Study 1089399 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine or Amitriptyline
Number of subjects: 24
Study 30784955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU twice daily)
Number of subjects: 40
Study 30784955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30784955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 40
Study 29947323 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powders (MNP) and nutrition counselling
Number of subjects: 4356
Study 29947323 — intervention group
Group type: COMPARATOR
Intervention: Nutrition counselling alone (Control)
Number of subjects: 4356
Study 26685869 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin system inhibitors (ASIs) at baseline
Number of subjects: 1545
Study 26685869 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib or pazopanib (control group)
Number of subjects: 1545
Study 24763890 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream containing 0.5% Aloe vera juice powder applied 3 times per day for 6 weeks
Number of subjects: 0
Study 24763890 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22495174 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD1 genetic variants (rs11746641, rs2168631, rs11749035) in slow nicotine metabolizers
Number of subjects: 0
Study 22495174 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal nicotine metabolizers)
Number of subjects: 0
Study 19504468 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal and mineral complex (HMC) - Astragalus membranaceus
Number of subjects: 48
Study 19504468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 17950564 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revision
Number of subjects: 1404
Study 17950564 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical revision
Number of subjects: 1404
Study 17950564 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly defined)
Number of subjects: 1404
Study 16268392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranir Whitening Wraps (WW2) used twice a day
Number of subjects: 76
Study 16268392 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Whitestrips Premium (WP2) used twice a day
Number of subjects: 76
Study 16268392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranir Whitening Wraps (WW1) used once a day
Number of subjects: 76
Study 16268392 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 12162472 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute TEAS alone
Number of subjects: 20
Study 12162472 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg morphine alone
Number of subjects: 20
Study 12162472 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute TEAS plus morphine
Number of subjects: 20
Study 12162472 — intervention group
Group type: COMPARATOR
Intervention: Saline plus no TEAS
Number of subjects: 20
Study 9861593 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of magnesium (as MgO)
Number of subjects: 38
Study 9861593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7635854 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine or Fluoxetine
Number of subjects: 53
Study 7635854 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 53
Study 2694119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0175 i.u..kg‐1 min‐1 calcitonin
Number of subjects: 7
Study 2694119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0350 i.u..kg‐1 min‐1 calcitonin
Number of subjects: 7
Study 2694119 — intervention group
Group type: EXPERIMENTAL
Intervention: calcitonin
Number of subjects: 7
Study 665564 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery
Number of subjects: 101
Study 665564 — intervention group
Group type: EXPERIMENTAL
Intervention: Included ileum
Number of subjects: 101
Study 665564 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfunctional jejunum
Number of subjects: 101
Study 665564 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfunctional ileum
Number of subjects: 101
Study 665564 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum magnesium levels
Number of subjects: 101
Study 665564 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total protein concentrations
Number of subjects: 101
Study 31900174 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 31900174 — intervention group
Group type: EXPERIMENTAL
Intervention: BASDAI50 responders
Number of subjects: 0
Study 31900174 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAS40 responders
Number of subjects: 0
Study 31685913 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified aerobic training with a load on the lower limbs (MG)
Number of subjects: 40
Study 31685913 — intervention group
Group type: COMPARATOR
Intervention: Conventional aerobic training (CG)
Number of subjects: 40
Study 26856247 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PD) treatment over 4.3 years
Number of subjects: 520
Study 26856247 — intervention group
Group type: COMPARATOR
Intervention: High-dose anti-metabolite treatment arm
Number of subjects: 520
Study 25633090 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil
Number of subjects: 31
Study 25633090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23386641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4800 IU daily
Number of subjects: 110
Study 23386641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 800 IU daily
Number of subjects: 110
Study 23386641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 23386641 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements to maintain total calcium intake of 1200-1400 mg/d
Number of subjects: 110
Study 20140470 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer cement restorations (single-surface)
Number of subjects: 43
Study 20140470 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer cement restorations (multiple-surface)
Number of subjects: 43
Study 19586229 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methadone-naloxone in a 50:1 ratio
Number of subjects: 15
Study 19586229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methadone-naloxone in a 50:1 ratio
Number of subjects: 15
Study 19586229 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 15
Study 17931936 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% hydrogen peroxide exposure (A1-A4 and B1-B4)
Number of subjects: 140
Study 17931936 — intervention group
Group type: COMPARATOR
Intervention: Distilled water immersion (A5 and B5)
Number of subjects: 140
Study 15818698 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0
Study 15818698 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 15818698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12354601 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE/PEI group (32 patients)
Number of subjects: 69
Study 12354601 — intervention group
Group type: COMPARATOR
Intervention: TACE group (37 patients)
Number of subjects: 69
Study 9443485 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone
Number of subjects: 66
Study 9443485 — intervention group
Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 66
Study 8006397 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week course of prednisolone followed by 2 weeks of no treatment and then a 12-week course of human lymphoblastoid interferon, 4 to 6 MU/m2 intramuscularly
Number of subjects: 120
Study 8006397 — intervention group
Group type: COMPARATOR
Intervention: Placebo given instead of prednisolone
Number of subjects: 120
Study 8006397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8006397 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week course of prednisolone followed by interferon
Number of subjects: 120
Study 2920071 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/kg of alcohol (12.5%, v/v)
Number of subjects: 0
Study 2920071 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study 812362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporins
Number of subjects: 48
Study 812362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30207254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 315
Study 30207254 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 315
Study 29241576 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 300 mL plum juice
Number of subjects: 24
Study 29241576 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 100 mL plum juice
Number of subjects: 24
Study 29241576 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 24
Study 25487567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg · kg(‐1) (Group D1)
Number of subjects: 90
Study 25487567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg · kg(‐1) (Group D2)
Number of subjects: 90
Study 25487567 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 90
Study 23924065 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 113
Study 23924065 — intervention group
Group type: COMPARATOR
Intervention: Active comparison condition (health education)
Number of subjects: 113
Study 23924065 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 113
Study 21539635 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAI ablation
Number of subjects: 118
Study 21539635 — intervention group
Group type: COMPARATOR
Intervention: CFE ablation
Number of subjects: 118
Study 21539635 — intervention group
Group type: COMPARATOR
Intervention: CFE ablation alone
Number of subjects: 118
Study 21539635 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAI ablation alone
Number of subjects: 118
Study 21539635 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAI + CFE ablation
Number of subjects: 118
Study 19532851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) patch
Number of subjects: 0
Study 19532851 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 16214329 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA n-3 supplementation (3.6 g daily for 3 months)
Number of subjects: 24
Study 16214329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil for 3 months)
Number of subjects: 24
Study 15541061 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP-BD sample
Number of subjects: 1000
Study 11425671 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) therapy
Number of subjects: 174
Study 11425671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 9260214 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz strain measles vaccine (SWMV)
Number of subjects: 39
Study 9260214 — intervention group
Group type: COMPARATOR
Intervention: Edmoston-Zagreb strain measles vaccine (EZMV)
Number of subjects: 39
Study 8033606 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoic acid (RA) alone at an oral dose of 45-60 mg/m2/d
Number of subjects: 107
Study 8033606 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy (RA and chemotherapy)
Number of subjects: 107
Study 8033606 — intervention group
Group type: COMPARATOR
Intervention: RA as continuation therapy (Group A)
Number of subjects: 107
Study 8033606 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Group B)
Number of subjects: 107
Study 8033606 — intervention group
Group type: COMPARATOR
Intervention: RA and chemotherapy alternately (Group C)
Number of subjects: 107
Study 2451816 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine 100 mg capsules
Number of subjects: 52
Study 2451816 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 50 mg capsules
Number of subjects: 52
Study 30141453 — intervention group
Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia (Group A)
Number of subjects: 60
Study 30141453 — intervention group
Group type: COMPARATOR
Intervention: Standard cardioplegia (Group B)
Number of subjects: 60
Study 27070985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified work-related rehabilitation aftercare (IWORAC)
Number of subjects: 307
Study 27070985 — intervention group
Group type: COMPARATOR
Intervention: Conventional intensified rehabilitation aftercare (IRAC)
Number of subjects: 307
Study 25156398 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training towards positive stimuli (ATP) combined with one-session treatment (OST)
Number of subjects: 37
Study 25156398 — intervention group
Group type: COMPARATOR
Intervention: Attention training control (ATC) combined with one-session treatment (OST)
Number of subjects: 37
Study 23735669 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally robotic Roux-en-Y gastric bypass (TR-RYGBP)
Number of subjects: 200
Study 23735669 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic gastric bypass
Number of subjects: 200
Study 20584565 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 g acetogenic fibers (acacia gum and pectin)
Number of subjects: 21
Study 20584565 — intervention group
Group type: COMPARATOR
Intervention: Control (without acetogenic fibers)
Number of subjects: 21
Study 20584565 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber treatment
Number of subjects: 21
Study 20584565 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 21
Study 18998824 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive BP-lowering group
Number of subjects: 1953
Study 18998824 — intervention group
Group type: COMPARATOR
Intervention: Less intensive BP-lowering group
Number of subjects: 1953
Study 15931646 — intervention group
Group type: EXPERIMENTAL
Intervention: 20.8 mg of sodium iron gluconate at the end of each dialysis session (Group A)
Number of subjects: 17
Study 15931646 — intervention group
Group type: EXPERIMENTAL
Intervention: 62.5 mg of sodium iron gluconate only at the end of the 1st dialysis session of the week (Group B)
Number of subjects: 17
Study 12514663 — intervention group
Group type: COMPARATOR
Intervention: Factor V Leiden mutation
Number of subjects: 395
Study 12514663 — intervention group
Group type: COMPARATOR
Intervention: Beta-fibrinogen 448 A allele
Number of subjects: 395
Study 12514663 — intervention group
Group type: COMPARATOR
Intervention: Prothrombin variant G20210A
Number of subjects: 395
Study 12514663 — intervention group
Group type: COMPARATOR
Intervention: Factor V Leiden and hypertension interaction
Number of subjects: 395
Study 10963500 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-1 levels before RP (T0)
Number of subjects: 57